{"id":70733,"date":"2026-05-12T10:13:05","date_gmt":"2026-05-12T10:13:05","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70733"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"ghrp-6","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/ghrp-6\/","title":{"rendered":"GHRP-6 Acetato"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es el acetato de GHRP-6?<\/h3>\n<p style=\"margin: 0;\"><strong>GHRP-6 Acetato<\/strong> (Growth Hormone Releasing Peptide 6) is a 6-amino-acid synthetic hexapeptide and one of the original growth hormone secretagogues, developed by Bowers and colleagues as the second-generation member of the GHRP series. It acts on the growth hormone secretagogue receptor (GHS-R1a) \u2014 the same receptor as endogenous ghrelin \u2014 producing pulsatile GH release alongside appetite stimulation. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">87616-84-0 (GHRP-6 base libre); suministrado en forma de sal acetato<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>46<\/sub>H<sub>56<\/sub>N<sub>12<\/sub>O<sub>6<\/sub> (forma libre; el acetato a\u00f1ade el contrai\u00f3n CH\u2083COOH)<sub>3<\/sub>1007.19 Da (forma libre)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">873.02 Da (base libre)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Secuencia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2<\/sub> (HwAWfK-NH<sub>2<\/sub>, 6 amino\u00e1cidos; contiene D-Trp en la posici\u00f3n 2 y D-Phe en la posici\u00f3n 5 para estabilidad proteol\u00edtica; terminaci\u00f3n C amidada)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Sal de acetato liofilizada (polvo blanco a blanquecino)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA bajo solicitud)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para stock de trabajo; \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2\u20138 \u00b0C, usar dentro de ~30 d\u00edas. Proteger de la luz. No congelar-descongelar la soluci\u00f3n reconstituida.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agua bacteriost\u00e1tica (recomendada) o agua est\u00e9ril para periodos de uso m\u00e1s cortos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es el Acetato de GHRP-6?<\/h2>\n<p><strong>GHRP-6<\/strong> (Growth Hormone Releasing Peptide 6) is a 6-amino-acid synthetic hexapeptide and one of the canonical members of the growth hormone secretagogue (GHS) peptide class. It was developed by Cyril Y. Bowers and colleagues at Tulane University as part of a structure-activity relationship programme designed to identify small peptides capable of stimulating pulsatile growth hormone release from the anterior pituitary \u2014 work that ultimately led to the discovery of the growth hormone secretagogue receptor and, indirectly, to the identification of endogenous ghrelin as its natural ligand in 1999 by Kojima et al. (Nature). The acetate counterion is used in pharmaceutical-grade lyophilization because it improves long-term peptide stability and aqueous solubility without altering pharmacology. The well-characterised sequence is HwAWfK-NH<sub>2<\/sub> (donde las letras min\u00fasculas denotan residuos de amino\u00e1cidos D), peso molecular 873.02 Da, f\u00f3rmula emp\u00edrica C<sub>46<\/sub>H<sub>56<\/sub>N<sub>12<\/sub>O<sub>6<\/sub>. Las dos sustituciones de amino\u00e1cidos D (D-Trp en la posici\u00f3n 2 y D-Phe en la posici\u00f3n 5) confieren resistencia a las proteasas end\u00f3genas y prolongan la vida media in vivo en comparaci\u00f3n con los an\u00e1logos totalmente L. La terminaci\u00f3n C est\u00e1 amidada, lo cual es esencial para la actividad del receptor. GHRP-6 no est\u00e1 <strong>no est\u00e1 aprobado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For the newer-generation receptor-selective analog without cortisol\/prolactin signalling, see our <a href=\"https:\/\/medsbase.com\/es\/ipamorelin\/\">Ipamorelina<\/a> p\u00e1gina de producto. <\/p>\n<h2>Mecanismo de Acci\u00f3n \u2014 Agonismo del Receptor GHS-R1a y el Pulso de GH<\/h2>\n<p>What makes GHRP-6 mechanistically distinctive among growth-axis peptides is its <strong>acci\u00f3n selectiva sobre el receptor secretagogo de hormona de crecimiento<\/strong> \u2014 the same receptor activated by endogenous ghrelin \u2014 rather than the GHRH receptor used by sermorelin and CJC-1295. The downstream effect is a pulsatile rather than tonic pattern of GH release in published studies:<\/p>\n<ul>\n<li><strong>Agonismo del receptor GHS-R1a en somatotrofos<\/strong> \u2014 GHRP-6 se une al receptor secretagogo de hormona de crecimiento tipo 1a (GHS-R1a, tambi\u00e9n llamado receptor de grelina) en los somatotrofos de la pituitaria anterior. La activaci\u00f3n del receptor se acopla a G\u03b1<sub>q\/11<\/sub> y a la fosfolipasa C, aumentando el calcio intracelular y desencadenando la exocitosis acoplada a despolarizaci\u00f3n de ves\u00edculas que contienen GH. La se\u00f1al se amplifica por la supresi\u00f3n del tono de somatostatina \u2014 GHRP-6 act\u00faa tanto en el somatotrofo como en las neuronas hipotal\u00e1micas de somatostatina, produciendo un pulso de GH mayor de lo que predecir\u00eda la estimulaci\u00f3n directa del somatotrofo sola.<\/li>\n<li><strong>Sinergia con la GHRH end\u00f3gena<\/strong> \u2014 Las v\u00edas de GHS-R y GHRH-R convergen intracelularmente pero utilizan diferentes sistemas de segundos mensajeros (PLC\/IP<sub>3<\/sub>\u00bfPuedo pedir acetato de oxitocina para env\u00edo internacional?<sup>2+<\/sup> vs adenylyl cyclase\/cAMP\/PKA), so GHRP-6 and GHRH analogs produce additive or synergistic GH release when combined. This is the rationale for the canonical &#8220;GHRP + GHRH analog&#8221; studies combinations: a GHS such as GHRP-6 paired with a GHRH analog such as <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> o <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a>. El est\u00edmulo combinado produce pulsos de GH sustancialmente mayores que cualquiera de los compuestos por separado.<\/li>\n<li><strong>Estimulaci\u00f3n del apetito fuera del objetivo y se\u00f1al modesta de cortisol\/prolactina<\/strong> \u2014 Because GHRP-6 acts on the ghrelin receptor, it inherits ghrelin&#8217;s appetite-stimulating effect \u2014 useful in cachexia studies, but a confound in cleaner GH-axis pharmacology. GHRP-6 also produces a modest increase in cortisol and prolactin secretion. The newer-generation selective analog Ipamorelin was specifically designed to eliminate this cortisol\/prolactin signal while preserving the GH effect \u2014 see the comparison section below.<\/li>\n<\/ul>\n<p>GHRP-6 has a plasma half-life of approximately 30\u201360 minutes, considerably longer than native ghrelin (~10\u201330 minutes) due to the D-amino-acid substitutions that resist proteolytic cleavage. Subcutaneous administration is the most-cited administration route in the published literature; intravenous and intranasal routes are also documented in mechanism-of-action studies. <\/p>\n<h2>Published Evidence<\/h2>\n<p>GHRP-6 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacolog\u00eda del eje de la hormona de crecimiento<\/strong> \u2014 pulsatile GH dynamics, somatotroph responsiveness, comparative GH-secretagogue studies; benchmark first-generation GHS in published GH-pulse architecture studies (Bowers et al., J Clin Endocrinol Metab; Smith et al., Science 1996)<\/li>\n<li><strong>Appetite and feeding behaviour studies<\/strong> \u2014 ghrelin-axis activation, food-intake assays in rodent models, cachexia models in tumour-bearing animals; canonical tool for separating ghrelin-mediated orexigenic signalling from other appetite pathways<\/li>\n<li><strong>Pituitary function studies<\/strong> \u2014 GH reserve testing in preclinical models, somatotroph hypertrophy \/ hyperplasia, mechanism-of-action data for novel GH secretagogues<\/li>\n<li><strong>Cachexia and wasting syndrome<\/strong> \u2014 caquexia en roedores con tumores, modelos de desgaste asociado a EPOC, preservaci\u00f3n de masa magra\/grasa mediante la activaci\u00f3n combinada del eje de GH y del apetito<\/li>\n<li><strong>Comparative GHS studies<\/strong> \u2014 evaluaci\u00f3n comparativa frente a an\u00e1logos m\u00e1s recientes, incluyendo <a href=\"https:\/\/medsbase.com\/es\/ipamorelin\/\">Ipamorelina<\/a> (selectivo del receptor sin cortisol\/prolactina), hexarelina (GHRP-6 modificado), GHRP-2 (an\u00e1logo alternativo de primera generaci\u00f3n) y GHS de mol\u00e9culas peque\u00f1as con actividad oral como MK-677<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 GHS-R expression on cardiomyocytes; published studies on cardiac ischaemia-reperfusion injury and cardiac function in GH-deficient models<\/li>\n<li><strong>Combined GHRP + GHRH use<\/strong> \u2014 protocolos sin\u00e9rgicos de liberaci\u00f3n de GH que combinan GHRP-6 con an\u00e1logos de GHRH como <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> o <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a> for maximal pulsatile GH studies stimulus.<\/li>\n<\/ul>\n<p>Para un contexto m\u00e1s amplio sobre c\u00f3mo encaja el GHRP-6 en el panorama de los p\u00e9ptidos del eje de crecimiento, consulte <a href=\"https:\/\/medsbase.com\/es\/ipamorelin\/\">Ipamorelina<\/a> como el an\u00e1logo selectivo del receptor de nueva generaci\u00f3n, <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a> for long-acting GHRH-axis studies, and <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> for shorter-acting GHRH use. Browse the full <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para compuestos relacionados. <\/p>\n<h2>Concentraciones y potencias disponibles<\/h2>\n<p>MedsBase stocks GHRP-6 Acetate in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Potencia del vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 short-cycle GH-pulse protocols, single-cohort studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de ciclo extendido, estudios multicohorte, menor coste por mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized acetate-salt powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume in rodent protocols. Because GHRP-6 dose ranges are in the 50\u2013300\u00a0mcg per administration regime, a single 5\u00a0mg vial supports many weeks of use at typical doses. <\/p>\n<h2>Comparativa \u2014 GHRP-6 vs Ipamorelina<\/h2>\n<p>GHRP-6 y <a href=\"https:\/\/medsbase.com\/es\/ipamorelin\/\">Ipamorelina<\/a> are the canonical first- and third-generation members of the growth hormone secretagogue peptide class, respectively, and are the most-cited head-to-head comparison in published GHS studies. They share the same receptor (GHS-R1a) and produce comparable GH pulses, but differ substantially in receptor selectivity and off-target signalling. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">GHRP-6<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Ipamorelina<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longitud<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">6 amino\u00e1cidos (hexap\u00e9ptido)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">5 amino\u00e1cidos (pentap\u00e9ptido)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Generaci\u00f3n<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GHS de primera generaci\u00f3n (~1984)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GHS de tercera generaci\u00f3n (~1998)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Receptor<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GHS-R1a (receptor de grelina)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GHS-R1a (receptor de grelina)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Pulso de GH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Liberaci\u00f3n puls\u00e1til intensa de GH<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Liberaci\u00f3n puls\u00e1til intensa de GH (comparable a GHRP-6)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Se\u00f1al de apetito<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">S\u00ed (efecto orexig\u00e9nico similar a la grelina)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Minimal or absent in published studies<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Cortisol \/ prolactina<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Modest increases (studies-relevant confound)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sin aumento medible: la principal ventaja de selectividad<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosis t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">50\u2013300 mcg, 1\u20133 veces al d\u00eda<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">100\u2013300 mcg, 1\u20133 veces al d\u00eda<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Vida media plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~30\u201360 min<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2 horas<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies where the appetite-stimulation signal is a feature (cachexia models, food-intake studies), GHRP-6 is preferred because the orexigenic effect is part of the studies target. For clean GH-axis pharmacology where cortisol and prolactin are confounding variables, Ipamorelin is preferred because the receptor-selectivity gains eliminate those off-target signals. Both are frequently paired with a GHRH analog (such as <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a>) for the canonical synergistic GH-pulse support protocol. <\/p>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> almacene los viales liofilizados refrigerados a 2\u20138 \u00b0C en su envase original para existencias de trabajo a corto plazo. Para almacenamiento a largo plazo sin abrir, congele a \u221220 \u00b0C. El acetato de GHRP-6 liofilizado es estable bajo refrigeraci\u00f3n hasta 24 meses y a \u221220 \u00b0C hasta 36 meses. Evite ciclos de congelaci\u00f3n-descongelaci\u00f3n en el polvo liofilizado. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers a 100\u00a0mcg dose; 0.1\u00a0mL delivers 250\u00a0mcg. Swirl gently \u2014 do <strong>ajuste<\/strong> shake \u2014 and allow 2\u20135 minutes for full dissolution. A correctly reconstituted solution should be clear and colourless. <strong>Despu\u00e9s de la reconstituci\u00f3n:<\/strong> almacene refrigerado a 2\u20138 \u00b0C y util\u00edcelo dentro de los 30 d\u00edas para una estabilidad \u00f3ptima. No congele la soluci\u00f3n reconstituida: los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan la integridad del p\u00e9ptido. Deseche cualquier vial que muestre turbidez, precipitado o decoloraci\u00f3n. <\/p>\n<h2 id=\"faqs\">Preguntas frecuentes<\/h2>\n<h3>What is GHRP-6 used for in studies?<\/h3>\n<p>GHRP-6 is used in studies investigating the growth hormone axis, pulsatile GH release dynamics, somatotroph responsiveness, ghrelin-axis pharmacology, appetite and feeding behaviour, cachexia and wasting syndromes, and combined GHRP + GHRH synergistic GH-release protocols. It is the canonical first-generation GHS peptide and the structural template from which Ipamorelin and other later-generation analogs were derived. The pharmaceutical-grade GHRP-6 sold here is <strong>ajuste<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia el GHRP-6 de la Ipamorelina?<\/h3>\n<p>Both act on the same receptor (GHS-R1a, the ghrelin receptor) and produce comparable pulsatile GH release, but they differ substantially in receptor selectivity and off-target signalling. GHRP-6 produces ghrelin-like appetite stimulation and modest increases in cortisol and prolactin. Ipamorelin was specifically designed to eliminate these off-target signals while preserving the GH effect \u2014 it produces minimal appetite signal and no measurable cortisol or prolactin increase in published studies. For clean GH-axis pharmacology, Ipamorelin is preferred; for studies involving appetite as a target, GHRP-6 remains useful. <\/p>\n<h3>\u00bfCu\u00e1l es la diferencia entre el GHRP-6 y el GHRP-2?<\/h3>\n<p>Both are first-generation hexapeptide growth hormone secretagogues from the Bowers clinical programme. GHRP-2 is somewhat more potent on a per-mg basis and produces slightly less appetite signal than GHRP-6, but the qualitative pharmacology is similar \u2014 both raise cortisol and prolactin modestly. GHRP-6 is the more extensively studied of the pair in published studies and remains the canonical first-generation reference compound. <\/p>\n<h3>What is the typical GHRP-6 dose?<\/h3>\n<p>Published preclinical protocols typically use 50\u2013300\u00a0mcg per administration, given subcutaneously 1\u20133 times daily for 2\u201312 week cycles. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 0.04\u00a0mL equals 100\u00a0mcg, 0.1\u00a0mL equals 250\u00a0mcg. <\/p>\n<h3>\u00bfEst\u00e1 el GHRP-6 aprobado por la FDA?<\/h3>\n<p>No. GHRP-6 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. <\/p>\n<h3>\u00bfC\u00f3mo se debe almacenar el acetato de GHRP-6?<\/h3>\n<p>Viales liofilizados: refrigerados a 2\u20138 \u00b0C para existencias de trabajo a corto plazo, o \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Soluci\u00f3n reconstituida: refrigerada a 2\u20138 \u00b0C, usar dentro de los 30 d\u00edas. No congele la soluci\u00f3n reconstituida: los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan el p\u00e9ptido. Proteja de la luz directa en todo momento. <\/p>\n<h3>\u00bfC\u00f3mo reconstituyo el GHRP-6?<\/h3>\n<p>Siga el procedimiento de reconstituci\u00f3n anterior. A\u00f1ada agua bacteriost\u00e1tica por la pared lateral del vial (no sobre el polvo liofilizado), agite suavemente y permita de 2 a 5 minutos para la disoluci\u00f3n completa. No <strong>ajuste<\/strong> agite el vial. Una soluci\u00f3n correctamente reconstituida es transparente e incolora. Para un vial de 5 mg + 2,0 mL de diluyente, la concentraci\u00f3n de trabajo es de 2,5 mg\/mL. <\/p>\n<h3>\u00bfQu\u00e9 concentraciones tiene MedsBase en stock?<\/h3>\n<p>MedsBase carries GHRP-6 Acetate in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>\u00bfPor qu\u00e9 el GHRP-6 tambi\u00e9n estimula el apetito?<\/h3>\n<p>El GHRP-6 se une al receptor secretagogo de la hormona del crecimiento (GHS-R1a), el mismo receptor que activa la grelina end\u00f3gena. Dado que la grelina es la principal hormona del hambre, cualquier agonista de su receptor hereda cierto grado de actividad orexig\u00e9nica (estimulante del apetito). Para los GHS de primera generaci\u00f3n como el GHRP-6 y el GHRP-2, el efecto sobre el apetito es considerable; en los an\u00e1logos selectivos de receptores de generaciones posteriores como el Ipamorelina, la se\u00f1al orexig\u00e9nica se atenu\u00f3 con \u00e9xito mediante optimizaci\u00f3n estructural. <\/p>\n<h3>Can GHRP-6 be paired with a GHRH analog in studies?<\/h3>\n<p>Yes \u2014 this is the canonical synergistic GH-pulse support protocol. GHRP-6 activates GHS-R1a (PLC\/IP<sub>3<\/sub>\u00bfPuedo pedir acetato de oxitocina para env\u00edo internacional?<sup>2+<\/sup> \u00bfEl GHRP-6 causa efectos secundarios en investigaci\u00f3n? <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> o <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a> Los principales efectos sobre el objetivo son la liberaci\u00f3n de GH y la estimulaci\u00f3n del apetito. Los hallazgos fuera del objetivo incluyen aumentos modestos de cortisol y prolactina (la principal confusi\u00f3n relevante para la investigaci\u00f3n en estudios del eje GH), enrojecimiento transitorio o reacciones locales en el lugar de la inyecci\u00f3n, y (rara vez) efectos mediados por GHS-R sobre la funci\u00f3n card\u00edaca a dosis altas. La se\u00f1al de cortisol\/prolactina es la principal raz\u00f3n por la que se desarrollaron an\u00e1logos selectivos de nueva generaci\u00f3n como la Ipamorelina. <\/p>\n<h3>Does GHRP-6 cause side reported effects?<\/h3>\n<p>The principal on-target effects are GH release and appetite stimulation. Off-target findings include modest cortisol and prolactin increases (the principal studies-relevant confound for GH-axis studies), transient flushing or local injection-site reactions, and (rarely) GHS-R-mediated effects on cardiac function at high doses. The cortisol\/prolactin signal is the main reason newer-generation selective analogs such as Ipamorelin were developed. <\/p>\n<h3>\u00bfCu\u00e1nto tiempo tarda el GHRP-6 en mostrar efectos en la investigaci\u00f3n precl\u00ednica?<\/h3>\n<p>In preclinical studies, GHRP-6 has a plasma half-life of approximately 30\u201360 minutes following subcutaneous administration. The extended half-life relative to endogenous ghrelin (~10\u201330 min) is due to the two D-amino-acid substitutions (D-Trp at position 2 and D-Phe at position 5) that resist proteolytic cleavage. The GH pulse outlasts plasma clearance because somatotroph desensitisation and receptor downregulation are slower processes. <\/p>\n<h3>How long does GHRP-6 take to show effects in preclinical studies?<\/h3>\n<p>S\u00ed. MedsBase env\u00eda GHRP-6 a todo el mundo desde nuestra red de env\u00edo de p\u00e9ptidos dedicada. Los pedidos que solo contienen p\u00e9ptidos califican para nuestro servicio de env\u00edo de p\u00e9ptidos independiente. Todos los pedidos se env\u00edan en embalajes con control de temperatura con seguimiento completo y est\u00e1n cubiertos por nuestro. <\/p>\n<h3>Can I order GHRP-6 for international shipping?<\/h3>\n<p>Yes. MedsBase ships GHRP-6 worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Growth-Axis, GH-Release, and Anabolic Studies<\/h2>\n<ul>\n<li><a href=\"\/es\/ipamorelin\/\"><strong>Ipamorelina<\/strong><\/a> \u2014 Pentap\u00e9ptido GHS selectivo de tercera generaci\u00f3n \u2014 pulso de GH limpio sin cortisol\/prolactina<\/li>\n<li><a href=\"\/es\/cjc-1295-with-dac\/\"><strong>CJC-1295 con DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 canonical GHRH-axis compound<\/li>\n<li><a href=\"\/es\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 Shorter-acting GHRH(1-29) analog \u2014 natural GH-pulse support<\/li>\n<li><a href=\"\/es\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 An\u00e1logo recombinante de IGF-1 con arginina larga \u2014 aguas abajo del eje GH\/IGF<\/li>\n<li><a href=\"\/es\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adipose tissue studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Lecturas adicionales<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explora el panorama de p\u00e9ptidos del eje GH<\/strong><\/p>\n<p style=\"margin: 0;\">Explora toda la <a href=\"https:\/\/medsbase.com\/es\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, con compuestos relacionados del eje GH incluyendo <a href=\"https:\/\/medsbase.com\/es\/ipamorelin\/\">Ipamorelina<\/a> for clean receptor-selective GHS studies, <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a> for long-acting GHRH use, and <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> for natural-pulse GHRH use.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Hexap\u00e9ptido GHS de primera generaci\u00f3n<br \/>\n\u2705 Agonista del receptor GHS-R1a \/ receptor de grelina<br \/>\n\u2705 Estimula la liberaci\u00f3n puls\u00e1til de GH<br \/>\n\u2705 Ghrelin-axis appetite studies<br \/>\n\u2705 Sin\u00e9rgico con an\u00e1logos de GHRH<\/p>\n<p><strong>GHRP-6 Acetato<\/strong> contiene compuesto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":70956,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6280,5441],"class_list":["post-70733","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-ghrp-6","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/70733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=70733"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/70956"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=70733"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=70733"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=70733"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=70733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}